Ursodiol (Ursodeoxycholic Acid): Clinical Guide
Primary Indications
Ursodiol is first-line therapy for primary biliary cholangitis (PBC) at 13-15 mg/kg/day, where it improves transplant-free survival and delays histologic progression. 1
Established Indications:
Primary Biliary Cholangitis (PBC)
- Dosing: 13-15 mg/kg/day divided in 2-3 doses 2, 3
- Improves serum bilirubin, alkaline phosphatase, aminotransferases, cholesterol, and IgM levels 2
- Delays histologic progression and improves transplant-free survival 1
- Continue therapy even with persistent alkaline phosphatase elevation—survival benefits persist 1
- Safe during pregnancy and breastfeeding; should be continued throughout pregnancy 4
Primary Sclerosing Cholangitis (PSC)
- Dosing: 15-20 mg/kg/day 4
- May improve serum liver tests and surrogate markers of prognosis
- Critical caveat: High-dose UDCA (28-30 mg/kg/day) is contraindicated in PSC—associated with increased adverse events, higher rates of transplantation, and worse outcomes 5, 6
- Safe during pregnancy; continue if already prescribed 4
Gallstone Dissolution
- Dosing: 8-10 mg/kg/day in 2-3 divided doses 3
- Patient selection criteria:
- Monitor with ultrasound at 6-month intervals first year 3
- If no partial dissolution by 12 months, discontinue—success unlikely 3
- Stone recurrence: 30-50% within 2-5 years after dissolution 3
Gallstone Prevention During Rapid Weight Loss
- Dosing: 600 mg/day (300 mg twice daily) 3
- Indicated for obese patients undergoing rapid weight loss (e.g., bariatric surgery)
- Reduces cholecystectomy and ERCP rates post-bariatric surgery 7
Intrahepatic Cholestasis of Pregnancy (ICP)
- Improves maternal pruritus (modest effect) 4
- Reduces spontaneous preterm birth risk in bile acids >40 μmol/L 4
- May be protective against stillbirth 4
- Safe during pregnancy and lactation 4
Dosing Regimens by Indication
| Indication | Dose | Frequency | Duration |
|---|---|---|---|
| PBC | 13-15 mg/kg/day | 2-3 divided doses | Indefinite |
| PSC | 15-20 mg/kg/day | 2-3 divided doses | Indefinite |
| Gallstone dissolution | 8-10 mg/kg/day | 2-3 divided doses | Up to 24 months |
| Gallstone prevention | 600 mg/day | 300 mg twice daily | During rapid weight loss period |
| ICP/Pruritus | Start 10 mg/kg/day, increase to 20 mg/kg/day | 2-3 divided doses | Until delivery |
Monitoring Parameters
For PBC/PSC:
- Serum bilirubin, alkaline phosphatase, aminotransferases, cholesterol at baseline
- Repeat liver biochemistries every 3-6 months initially, then every 6-12 months once stable
- Monitor for symptom improvement (though UDCA does not significantly improve fatigue or pruritus in PBC) 2
For Gallstone Dissolution:
- Ultrasound at 6-month intervals during first year 3
- If partial dissolution seen, continue therapy and confirm complete dissolution with repeat ultrasound 1-3 months later 3
- Discontinue if no partial dissolution by 12 months 3
- Monitor for stone recurrence with serial ultrasounds after dissolution 3
For ICP:
- Measure serum bile acids weekly from 32 weeks gestation 4
- Bile acids >100 μmol/L: plan delivery at 35 weeks to reduce stillbirth risk 4
Critical Precautions and Contraindications
Absolute Contraindications:
- Calcified gallstones (will not dissolve) 3
- Complete biliary obstruction
- Acute cholecystitis or cholangitis
Relative Contraindications/Warnings:
- Do NOT use high-dose UDCA (>25 mg/kg/day) in PSC—associated with worse outcomes 5, 6
- Gallbladder non-visualization during treatment predicts failure; discontinue therapy 3
- Stones >20 mm rarely dissolve 3
- Short bowel syndrome or resected terminal ileum reduces absorption and efficacy 8
Drug Interactions:
- Separate from cholestyramine/colestipol by at least 4 hours—bile acid sequestrants bind UDCA and reduce absorption 4
- Aluminum-based antacids may reduce UDCA absorption
Safety Profile
Common Side Effects:
- Dose-dependent diarrhea (most common) 9
- Nausea (18% report as barrier to compliance) 7
- Generally well-tolerated with minimal serious adverse events 1
Pregnancy and Lactation:
- FDA Category B (safe in pregnancy)
- Strongly recommended to continue during pregnancy for PBC and PSC 4
- Safe during breastfeeding 4
Vitamin K Monitoring:
- Cholestasis and concurrent use of cholestyramine/rifampicin increase vitamin K deficiency risk
- Correct vitamin K deficiency when present 4
Common Clinical Pitfalls
Using high-dose UDCA in PSC: Doses >25 mg/kg/day worsen outcomes—stick to 15-20 mg/kg/day maximum 5, 6
Discontinuing UDCA in pregnancy: This is a critical error—UDCA is safe and should be continued 4
Expecting symptom improvement in PBC: UDCA improves biochemistry and histology but does not significantly improve fatigue or pruritus 2
Stopping UDCA when alkaline phosphatase remains elevated: Continue therapy—survival benefits persist even without complete biochemical response 1
Attempting gallstone dissolution beyond 12 months without partial response: Futile—discontinue if no partial dissolution by 1 year 3
Co-administering with cholestyramine without time separation: Reduces UDCA absorption—separate by ≥4 hours 4
Cost barriers: 45% of patients cite cost as compliance barrier 7—address affordability upfront